Cesar Martin Castro, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biosensing Techniques | 9 | 2023 | 668 | 1.250 |
Why?
|
| Neoplastic Cells, Circulating | 7 | 2023 | 934 | 1.160 |
Why?
|
| Magnetic Resonance Spectroscopy | 7 | 2018 | 3760 | 0.910 |
Why?
|
| Exosomes | 5 | 2017 | 417 | 0.820 |
Why?
|
| Ovarian Neoplasms | 13 | 2023 | 4838 | 0.820 |
Why?
|
| Nanotechnology | 3 | 2017 | 710 | 0.760 |
Why?
|
| Surface Plasmon Resonance | 3 | 2020 | 274 | 0.690 |
Why?
|
| Holography | 2 | 2018 | 84 | 0.690 |
Why?
|
| Point-of-Care Systems | 11 | 2023 | 1177 | 0.680 |
Why?
|
| Magnetite Nanoparticles | 3 | 2017 | 321 | 0.620 |
Why?
|
| Microfluidics | 4 | 2017 | 662 | 0.600 |
Why?
|
| Miniaturization | 2 | 2013 | 164 | 0.540 |
Why?
|
| Cervix Uteri | 1 | 2019 | 590 | 0.530 |
Why?
|
| Early Detection of Cancer | 3 | 2019 | 3086 | 0.530 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2016 | 602 | 0.480 |
Why?
|
| Staining and Labeling | 2 | 2022 | 1100 | 0.450 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 1375 | 0.390 |
Why?
|
| Lymphoma | 2 | 2016 | 1877 | 0.360 |
Why?
|
| Flow Cytometry | 1 | 2020 | 5974 | 0.360 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2019 | 2020 | 0.350 |
Why?
|
| Nanoparticles | 7 | 2019 | 1905 | 0.350 |
Why?
|
| Microfluidic Analytical Techniques | 5 | 2017 | 828 | 0.340 |
Why?
|
| Endometrial Neoplasms | 3 | 2023 | 1353 | 0.330 |
Why?
|
| Nanomedicine | 1 | 2011 | 304 | 0.330 |
Why?
|
| Electrochemical Techniques | 2 | 2021 | 98 | 0.320 |
Why?
|
| Nucleic Acids | 2 | 2023 | 182 | 0.310 |
Why?
|
| Neoplasms | 9 | 2023 | 21683 | 0.290 |
Why?
|
| Indoles | 3 | 2021 | 1839 | 0.270 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2023 | 59 | 0.230 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2017 | 484 | 0.210 |
Why?
|
| Membrane Proteins | 1 | 2019 | 7880 | 0.200 |
Why?
|
| Uteroglobin | 1 | 2000 | 58 | 0.190 |
Why?
|
| Biotinylation | 1 | 2020 | 179 | 0.190 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2020 | 1094 | 0.180 |
Why?
|
| Microspheres | 3 | 2017 | 777 | 0.170 |
Why?
|
| Breast Neoplasms | 6 | 2022 | 20822 | 0.170 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2023 | 450 | 0.170 |
Why?
|
| Neurosecretory Systems | 1 | 2000 | 231 | 0.170 |
Why?
|
| Substance Abuse Detection | 1 | 2021 | 283 | 0.170 |
Why?
|
| Human papillomavirus 18 | 1 | 2019 | 128 | 0.170 |
Why?
|
| Humans | 64 | 2023 | 744343 | 0.160 |
Why?
|
| Immunoconjugates | 2 | 2023 | 901 | 0.160 |
Why?
|
| Biological Assay | 2 | 2021 | 652 | 0.150 |
Why?
|
| Food Safety | 1 | 2017 | 22 | 0.150 |
Why?
|
| Human papillomavirus 16 | 1 | 2019 | 262 | 0.150 |
Why?
|
| Bile Duct Neoplasms | 1 | 2023 | 567 | 0.150 |
Why?
|
| Cholangiocarcinoma | 1 | 2023 | 516 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 9239 | 0.150 |
Why?
|
| Peritoneal Neoplasms | 1 | 2023 | 665 | 0.150 |
Why?
|
| Inorganic Chemicals | 1 | 2016 | 10 | 0.150 |
Why?
|
| CA-19-9 Antigen | 1 | 2017 | 111 | 0.150 |
Why?
|
| Neoplasm Proteins | 3 | 2014 | 3703 | 0.140 |
Why?
|
| Dengue Virus | 1 | 2018 | 204 | 0.140 |
Why?
|
| Capsules | 1 | 2017 | 196 | 0.140 |
Why?
|
| Cell Fractionation | 1 | 2017 | 252 | 0.140 |
Why?
|
| Sepsis | 2 | 2023 | 2593 | 0.140 |
Why?
|
| Plastics | 1 | 2017 | 123 | 0.140 |
Why?
|
| Filtration | 1 | 2017 | 234 | 0.140 |
Why?
|
| Fluorescence Polarization | 1 | 2016 | 132 | 0.140 |
Why?
|
| Silicon Dioxide | 1 | 2017 | 213 | 0.140 |
Why?
|
| Influenza in Birds | 1 | 2016 | 75 | 0.130 |
Why?
|
| Cell Line, Tumor | 9 | 2019 | 16689 | 0.130 |
Why?
|
| Biomimetics | 1 | 2017 | 172 | 0.130 |
Why?
|
| Computers, Handheld | 1 | 2017 | 208 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 3 | 2020 | 5256 | 0.130 |
Why?
|
| Dengue | 1 | 2018 | 256 | 0.130 |
Why?
|
| Ascites | 2 | 2015 | 344 | 0.130 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2017 | 319 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 11524 | 0.120 |
Why?
|
| Genes, BRCA2 | 1 | 2017 | 618 | 0.120 |
Why?
|
| Cathepsin E | 1 | 2013 | 3 | 0.120 |
Why?
|
| Proteins | 2 | 2017 | 6103 | 0.120 |
Why?
|
| Bacteria | 2 | 2016 | 2114 | 0.120 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 13695 | 0.120 |
Why?
|
| Cyclooctanes | 1 | 2013 | 32 | 0.120 |
Why?
|
| Genes, BRCA1 | 1 | 2017 | 781 | 0.110 |
Why?
|
| Papillomaviridae | 1 | 2019 | 1119 | 0.110 |
Why?
|
| Catheter-Related Infections | 1 | 2016 | 252 | 0.110 |
Why?
|
| Ribose | 2 | 2023 | 68 | 0.110 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2017 | 428 | 0.110 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2015 | 402 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2018 | 8949 | 0.110 |
Why?
|
| Female | 31 | 2023 | 380194 | 0.110 |
Why?
|
| Bacterial Typing Techniques | 1 | 2013 | 256 | 0.110 |
Why?
|
| Influenza A virus | 1 | 2016 | 456 | 0.110 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2015 | 730 | 0.110 |
Why?
|
| Boron Compounds | 1 | 2013 | 178 | 0.100 |
Why?
|
| Cerebrospinal Fluid | 1 | 2015 | 534 | 0.100 |
Why?
|
| Protein Array Analysis | 1 | 2014 | 411 | 0.100 |
Why?
|
| Cell-Derived Microparticles | 1 | 2013 | 168 | 0.100 |
Why?
|
| Folate Receptor 1 | 2 | 2023 | 36 | 0.100 |
Why?
|
| Ferric Compounds | 1 | 2013 | 374 | 0.100 |
Why?
|
| Ritonavir | 1 | 2013 | 322 | 0.100 |
Why?
|
| Protein Isoforms | 1 | 2016 | 1730 | 0.100 |
Why?
|
| Factor XIII Deficiency | 1 | 2010 | 16 | 0.100 |
Why?
|
| HIV Protease Inhibitors | 1 | 2013 | 430 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 1972 | 0.090 |
Why?
|
| Genital Neoplasms, Female | 1 | 2016 | 523 | 0.090 |
Why?
|
| Food Hypersensitivity | 1 | 2017 | 622 | 0.090 |
Why?
|
| Dependovirus | 1 | 2015 | 706 | 0.090 |
Why?
|
| Allergens | 1 | 2017 | 1320 | 0.090 |
Why?
|
| Mammography | 1 | 2021 | 2476 | 0.090 |
Why?
|
| Polymers | 1 | 2017 | 1621 | 0.090 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 1788 | 0.090 |
Why?
|
| Lung | 2 | 2013 | 9856 | 0.080 |
Why?
|
| Viral Proteins | 1 | 2016 | 1900 | 0.080 |
Why?
|
| Sensitivity and Specificity | 4 | 2020 | 14722 | 0.080 |
Why?
|
| Antibodies | 2 | 2014 | 2460 | 0.080 |
Why?
|
| High-Throughput Screening Assays | 1 | 2014 | 944 | 0.080 |
Why?
|
| Precancerous Conditions | 1 | 2015 | 975 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 3557 | 0.070 |
Why?
|
| RNA | 1 | 2017 | 2749 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2023 | 3752 | 0.070 |
Why?
|
| DNA | 3 | 2023 | 7301 | 0.070 |
Why?
|
| Hydrogels | 2 | 2023 | 724 | 0.070 |
Why?
|
| Biopsy | 3 | 2013 | 6756 | 0.070 |
Why?
|
| Area Under Curve | 2 | 2021 | 1654 | 0.070 |
Why?
|
| Cross Infection | 1 | 2016 | 1416 | 0.070 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2015 | 895 | 0.070 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2017 | 1634 | 0.070 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 57776 | 0.070 |
Why?
|
| Paclitaxel | 2 | 2023 | 1708 | 0.070 |
Why?
|
| Fluorescent Dyes | 1 | 2013 | 1917 | 0.060 |
Why?
|
| Ligands | 2 | 2022 | 3282 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2016 | 3474 | 0.060 |
Why?
|
| Algorithms | 3 | 2022 | 13881 | 0.060 |
Why?
|
| Graft Rejection | 1 | 2017 | 4397 | 0.060 |
Why?
|
| Aged | 13 | 2022 | 163280 | 0.060 |
Why?
|
| Pathology, Molecular | 2 | 2018 | 326 | 0.060 |
Why?
|
| Erythrocytes | 1 | 2013 | 2455 | 0.060 |
Why?
|
| Tissue Array Analysis | 2 | 2016 | 553 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2022 | 2938 | 0.060 |
Why?
|
| Plasma | 2 | 2022 | 575 | 0.060 |
Why?
|
| Middle Aged | 14 | 2023 | 213383 | 0.060 |
Why?
|
| Electroosmosis | 1 | 2023 | 11 | 0.060 |
Why?
|
| Proteomics | 3 | 2023 | 3638 | 0.060 |
Why?
|
| Equipment Design | 3 | 2017 | 3582 | 0.060 |
Why?
|
| Papillomavirus Infections | 1 | 2015 | 1587 | 0.060 |
Why?
|
| Fallopian Tubes | 1 | 2023 | 182 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 4851 | 0.050 |
Why?
|
| Diphosphates | 1 | 2022 | 88 | 0.050 |
Why?
|
| BRCA1 Protein | 2 | 2021 | 1149 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2015 | 19905 | 0.050 |
Why?
|
| Radiography | 1 | 2013 | 7023 | 0.050 |
Why?
|
| Antibodies, Immobilized | 1 | 2021 | 26 | 0.050 |
Why?
|
| Adult | 13 | 2021 | 214055 | 0.050 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2023 | 295 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 6773 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2023 | 440 | 0.050 |
Why?
|
| Carboplatin | 1 | 2023 | 801 | 0.050 |
Why?
|
| Time Factors | 3 | 2016 | 40075 | 0.040 |
Why?
|
| Phthalazines | 1 | 2022 | 363 | 0.040 |
Why?
|
| Maytansine | 1 | 2020 | 80 | 0.040 |
Why?
|
| Platinum | 1 | 2021 | 233 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2022 | 426 | 0.040 |
Why?
|
| Gold | 1 | 2023 | 484 | 0.040 |
Why?
|
| Luminescence | 1 | 2019 | 137 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 1 | 2010 | 2647 | 0.040 |
Why?
|
| Lipoproteins, LDL | 1 | 2022 | 640 | 0.040 |
Why?
|
| Patient Advocacy | 1 | 2001 | 353 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2022 | 1185 | 0.040 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2020 | 247 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2020 | 408 | 0.040 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2000 | 306 | 0.040 |
Why?
|
| Inflammation | 1 | 2017 | 10638 | 0.040 |
Why?
|
| Botswana | 1 | 2021 | 1040 | 0.040 |
Why?
|
| Saliva | 1 | 2021 | 809 | 0.040 |
Why?
|
| Electronics | 1 | 2018 | 322 | 0.040 |
Why?
|
| Complementary Therapies | 1 | 2001 | 486 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2023 | 5172 | 0.040 |
Why?
|
| Tropism | 1 | 2015 | 41 | 0.030 |
Why?
|
| Birds | 1 | 2016 | 163 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2023 | 1676 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 2 | 2023 | 9274 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2019 | 1792 | 0.030 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2016 | 407 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 1157 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 10943 | 0.030 |
Why?
|
| Kidney | 2 | 2023 | 7186 | 0.030 |
Why?
|
| Recurrence | 2 | 2021 | 8340 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2023 | 3479 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2022 | 2187 | 0.030 |
Why?
|
| Receptors, Peptide | 1 | 2015 | 272 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2015 | 314 | 0.030 |
Why?
|
| Surface Properties | 1 | 2017 | 1184 | 0.030 |
Why?
|
| Ascitic Fluid | 1 | 2014 | 192 | 0.030 |
Why?
|
| Physician's Role | 1 | 2001 | 943 | 0.030 |
Why?
|
| ROC Curve | 1 | 2021 | 3527 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2015 | 351 | 0.030 |
Why?
|
| Click Chemistry | 1 | 2013 | 95 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2021 | 3913 | 0.030 |
Why?
|
| Metals | 1 | 2017 | 719 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 2016 | 862 | 0.030 |
Why?
|
| Receptor, erbB-2 | 1 | 2022 | 2416 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 459 | 0.030 |
Why?
|
| BRCA2 Protein | 1 | 2017 | 794 | 0.030 |
Why?
|
| Erythrocyte Membrane | 1 | 2013 | 442 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 2728 | 0.030 |
Why?
|
| Alphapapillomavirus | 1 | 2015 | 221 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 890 | 0.030 |
Why?
|
| Transgenes | 1 | 2015 | 1009 | 0.030 |
Why?
|
| Mice | 4 | 2023 | 81183 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 4933 | 0.020 |
Why?
|
| Thalamic Diseases | 1 | 2010 | 16 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2016 | 1117 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 3870 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 6895 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2018 | 6314 | 0.020 |
Why?
|
| Magnetics | 1 | 2013 | 606 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 6538 | 0.020 |
Why?
|
| Muscles | 1 | 2015 | 1614 | 0.020 |
Why?
|
| Exons | 1 | 2016 | 2437 | 0.020 |
Why?
|
| Phospholipids | 1 | 2013 | 784 | 0.020 |
Why?
|
| Blood Coagulation Tests | 1 | 2010 | 263 | 0.020 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2013 | 954 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2015 | 1915 | 0.020 |
Why?
|
| Reference Standards | 1 | 2013 | 1025 | 0.020 |
Why?
|
| Animals | 5 | 2023 | 168757 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 13102 | 0.020 |
Why?
|
| Male | 6 | 2021 | 350118 | 0.020 |
Why?
|
| International Normalized Ratio | 1 | 2010 | 367 | 0.020 |
Why?
|
| Species Specificity | 1 | 2013 | 2478 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2023 | 11031 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 2214 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2015 | 10481 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2000 | 3690 | 0.020 |
Why?
|
| Prognosis | 2 | 2021 | 29063 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 1376 | 0.020 |
Why?
|
| Cytokines | 1 | 2023 | 7322 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2018 | 2921 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2013 | 1534 | 0.020 |
Why?
|
| Mucin-1 | 1 | 2012 | 543 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2013 | 1301 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 10252 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2022 | 13033 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 3772 | 0.020 |
Why?
|
| Cell Separation | 1 | 2012 | 1751 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 1477 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 2077 | 0.020 |
Why?
|
| Genotype | 1 | 2000 | 12951 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2001 | 4245 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2000 | 14557 | 0.020 |
Why?
|
| United States | 3 | 2023 | 69872 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 13989 | 0.020 |
Why?
|
| Mass Screening | 1 | 2021 | 5255 | 0.020 |
Why?
|
| Cerebral Angiography | 1 | 2010 | 1285 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2016 | 3176 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2013 | 2132 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2022 | 63114 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2020 | 53288 | 0.020 |
Why?
|
| Software | 1 | 2018 | 4443 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2010 | 1442 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2023 | 77449 | 0.010 |
Why?
|
| Single-Cell Analysis | 1 | 2014 | 2183 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2000 | 11483 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2013 | 3086 | 0.010 |
Why?
|
| Cell Line | 1 | 2017 | 15997 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 2017 | 4251 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 5391 | 0.010 |
Why?
|
| Base Sequence | 1 | 2013 | 12797 | 0.010 |
Why?
|
| Young Adult | 2 | 2021 | 56430 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2015 | 23403 | 0.010 |
Why?
|
| Social Conditions | 1 | 2001 | 126 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 8428 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 18111 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 10180 | 0.010 |
Why?
|
| Marketing of Health Services | 1 | 2001 | 153 | 0.010 |
Why?
|
| Critical Care | 1 | 2010 | 2647 | 0.010 |
Why?
|
| Telemedicine | 1 | 2015 | 2872 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 5535 | 0.010 |
Why?
|
| Public Opinion | 1 | 2001 | 477 | 0.010 |
Why?
|
| Phenotype | 1 | 2013 | 16365 | 0.010 |
Why?
|
| Adolescent | 1 | 2021 | 85781 | 0.010 |
Why?
|
| United States Food and Drug Administration | 1 | 2001 | 1584 | 0.010 |
Why?
|
| Mutation | 1 | 2016 | 29786 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2013 | 40561 | 0.010 |
Why?
|
| Caregivers | 1 | 2001 | 2094 | 0.010 |
Why?
|
| Medical Oncology | 1 | 2001 | 2265 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2001 | 3396 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 20129 | 0.000 |
Why?
|